Community Consensus
Do you like MOTS-c?
Reflects reader sentiment, not medical advice or a recommendation.
Quick answer
There is no clinically established MOTS-c dosage. MOTS-c is an investigational compound that is not FDA-approved and has never completed a human clinical trial, so every 'dosage chart' online is based on animal studies, one small pilot, or unregulated community use, not validated medical protocols. The commonly cited ~5–10 mg/week subcutaneous figure comes from research-peptide communities, not human research. Any use should involve a licensed medical provider.
Key takeaways
- There is no established clinical MOTS-c dose; no human clinical trial has been completed.
- MOTS-c is an investigational compound, not FDA-approved, legal only for research.
- The widely cited ~5–10 mg/week figure comes from community/vendor sources, not human studies.
- Actual research is thin: one small 2023 IV pilot, an analog (CB4211) Phase 1, and mouse studies.
- This is educational reporting, not a protocol; any use belongs with a licensed clinician.
⚠️ Important: MOTS-c is an investigational research compound. It is not approved by the FDA for human use, and no completed clinical trials have established a safe or effective dose. This article reports, for education, what doses appear across research and community sources. It is not medical advice, not a protocol, and not an endorsement of use. Always consult a licensed medical provider.
Is there an established MOTS-c dosage?
The honest answer is no. Despite the many “MOTS-c dosage charts” floating around online, there is no clinically established dose, because MOTS-c has never completed a human clinical trial. It remains an investigational compound, legal only for research, and the FDA has not evaluated it for safety or efficacy in people. Any dosing figure you see, including in this article, is derived from preclinical (animal) studies, a single small pilot, or unregulated research-peptide community use. None of it comes from validated medical protocols.
What the actual research has used
Here’s the real state of the evidence, which is far thinner than the confident charts suggest:
| Source / context | Dose reported | What it actually is |
|---|---|---|
| 2023 human pilot study | Intravenous MOTS-c for 7 days | Small, short study in insulin-resistant men; IV (not subcutaneous); not replicated |
| CohBar CB4211 (Phase 1) | A MOTS-c analog, not MOTS-c itself | Early trial in fatty-liver patients; a modified molecule, so not directly transferable |
| Animal (mouse) studies | ~5–15 mg/kg body weight | Rodent dosing does not convert directly to humans (requires allometric scaling) |
| Research-peptide community protocols | Commonly cited ~5–10 mg/week subcutaneous | Unregulated, anecdotal; not clinically validated |
Notice the gap. The widely repeated “5–10 mg per week” figure comes from the bottom row, community and vendor sources, not from the human research. That distinction is the entire point.
Why we don’t publish a prescriptive protocol
MitoHacker covers the science of mitochondrial compounds for education. For an unapproved injectable research peptide, handing you a step-by-step “inject X on this schedule” protocol would mean presenting unvalidated medical instructions as if they were established. We won’t do that. If you are considering MOTS-c, that decision belongs with a licensed medical provider who can weigh your individual situation, source quality, and the (currently limited) safety data.
Benefits and side effects (in brief)
MOTS-c is studied as an “exercise-mimetic” mitochondrial-derived peptide that activates AMPK. See our full MOTS-c science guide for the mechanism and research. Reported side effects (from limited data and community use) are generally mild: injection-site reactions, occasional fatigue or nausea. But the safety profile in humans is not well characterized, and the FDA has flagged quality risks (impurities, immunogenicity) in compounded peptide products.
The bottom line
There is no established MOTS-c dose, because the human research doesn’t exist yet. The dosing charts circulating online reflect community practice, not medical consensus. Treat any figure with appropriate skepticism, remember that it’s an investigational compound, and involve a licensed clinician before considering use.
Educational content only, not medical advice, and not evaluated by the FDA. MOTS-c is an investigational research compound, and this article does not provide a dosing protocol. Consult a licensed medical provider before considering any research compound.
Frequently asked questions
Is there a standard MOTS-c dosage?
No. Because MOTS-c has never completed a human clinical trial and is not FDA-approved, there is no clinically established or standard dose. The dosing charts online are based on animal data, a single small pilot, or unregulated community use, not validated medical protocols.
How much MOTS-c do people report using per week?
Research-peptide community protocols commonly cite around 5–10 mg per week subcutaneously, often in 8–12 week cycles. It's important to understand this as anecdotal, unregulated practice, not a clinically validated dose. We report it for education, not as a recommendation.
Is MOTS-c FDA approved?
No. MOTS-c is an investigational research compound. It has not completed the drug-approval process and is not approved for human use. The FDA has also flagged quality risks (impurities, immunogenicity) in compounded peptide products.
Why doesn't this page give a MOTS-c protocol?
Because MOTS-c is an unapproved injectable research peptide with no established human dose, providing a step-by-step protocol would present unvalidated instructions as if they were medical consensus. Decisions about MOTS-c should be made with a licensed medical provider.
References
- 1.Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- 2.Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470.
- 3.CohBar, Inc. CB4211 (a MOTS-c analog): Phase 1a/1b clinical trial in NASH/obesity (company-reported safety and ALT/AST reductions).
- 4.U.S. FDA. Certain bulk drug substances proposed for use in compounding: safety-risk considerations for peptide products (immunogenicity, impurities, characterization).